SCHEMBL3666481

SCHEMBL3666481

O=C1CCN(C2CCC2)c2nc(Cl)ncc2N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PIK3CA P42336 2/20 0.33
MTOR P42345 1/20 0.33
JAK2 O60674 2/20 0.33
PIK3R1 P27986 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
OGFRL1 Q5TC84 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135929 0.97 KDM4E (0.36) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL1203575 0.97 KDM4E (0.36) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL3544001 0.96 KDM4E (0.37) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL4079840 0.86 KDM4E (0.34) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL19105526 0.85 KDM4E (0.43) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL13261895 0.85 KDM4E (0.43) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL3668034 0.85 KDM4E (0.43) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL4076292 0.84 PIK3CA (0.33) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL3230980 0.84 OPRM1 (0.41) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL16473281 0.82 TTK (0.37) KDM4EALDH1A1HPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139892-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. Hoffmann-Roche AG (CH) 2010-01-06 EP disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
WO-2008113711-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-25 WO disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 KDM4E 1150/4885ALDH1A1 1365/4885HPGD 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.